Research Article
Echocardiography in Confirmed and Highly Suspected Symptomatic COVID-19 Patients and Its Impact on Treatment Change
Table 3
Biological characteristics of the patients included.
| Characteristics | All TTE/TEE patients (n = 56) | According to treatment change | value | TTE/TEE patients with treatment change induced by the TTE N = 9 (16%) | TTE/TEE patients without treatment change induced by the TTE N = 47 (84%) |
| Creatinine, median (IQR), µmol/l | 80 (58.5–124) | 90 (77–126) | 74 (58–122) | 0.4961 | Hs Troponin T, median (IQR), pg/ml | 21 (11.8–57) | 101.5 (30.3–111.2) | 20.3 (11.6–43.5) | 0.0506 | NT-pro BNP, median (IQR), pg/ml | 628 (177–2530) | 750 (339–4038) | 552.5 (155.5–2138.5) | 0.3197 | D-dimer, median (IQR), ng/ml | 2970 (1130–11620) | 20000 (2690–20000) | 2770 (1350–9330) | 0.0142 | Fibrinogen, median (IQR), g/l | 7.84 (5.72–10.2) | 7.15 (5.17–7.95) | 8.64 (5.89–10.2) | 0.4111 | Blood type, N (%) | O+: 17 (46.0) A+: 9 (24.3) A−: 2 (5.4) AB+: 2 (5.4) B+: 7 (18.9) | O+: 4 (57.1) A+: 0 A−: 1 (14.3) AB+: 1 (14.3) B+: 1 (14.3) | O+: 13 (43.4) A+: 9 (30.0) A−: 1 (3.3) AB+: 1 (3.3) B+: 6 (20.0) | 0.2900 |
|
|
NT-pro BNP : N-terminal pro B natriuretic peptide; Hs Troponin T: high-sensitivity cardiac Troponin T.
|